All In Biotech

Drug Trial Radar · NCT02195700

Aim to Reduce Movements in Tardive Dyskinesia

A Randomized, Double-Blind, Placebo-Controlled Study of SD-809 (Deutetrabenazine) for the Treatment of Moderate to Severe Tardive Dyskinesia

Last checked: Nov 20, 2026Latest source record: Nov 9, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 117 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

117

Actual

Start

Jun 2014

Primary completion

May 2015

Study completion May 2015

Sponsor

Lead sponsor
Auspex Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Jul 21, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.

Conditions

  • Tardive Dyskinesia

Interventions

  • SD-809Drug

    SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.

  • PlaceboDrug

    Placebo tablets taken twice daily for 12 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in Centrally Read Abnormal Involuntary Movement Scale (AIMS) Score From Baseline to Week 12 Using Mixed Model Repeated Measures (MMRM) AnalysisTime frame: Day 0 (Baseline), Weeks 2, 4, 6, 9 and 12

Locations

41 sites in 4 countries. Site status is shown where the registry gives one.

  • Site not named

    Tuscaloosa, Alabama

  • Site not named

    Anaheim, California

  • Site not named

    Glendale, California

  • Site not named

    Oceanside, California

  • Site not named

    Orange, California

  • Site not named

    San Bernardino, California

  • Site not named

    San Diego, California

  • Site not named

    Denver, Colorado

  • Site not named

    New Haven, Connecticut

  • Site not named

    Stamford, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Boca Raton, Florida

  • Site not named

    Gainesville, Florida

  • Site not named

    Lake City, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Port Charlotte, Florida

  • Site not named

    Chicago, Illinois

  • Site not named

    Baltimore, Maryland

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Kansas City, Missouri

  • Site not named

    St Louis, Missouri

  • Site not named

    Albuquerque, New Mexico

  • Site not named

    Asheville, North Carolina

  • Site not named

    Durham, North Carolina

  • Site not named

    Raleigh, North Carolina

  • Site not named

    Cleveland, Ohio

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Charleston, South Carolina

  • Site not named

    Memphis, Tennessee

  • Site not named

    Fort Worth, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Prague, Czechia

  • Site not named

    Gdansk, Poland

  • Site not named

    Katowice, Poland

  • Site not named

    Krakow, Poland

  • Site not named

    Lodz, Poland

  • Site not named

    Lublin, Poland

  • Site not named

    Torun, Poland

  • Site not named

    Domaša, Slovakia

Showing 40 of 41 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.